VistaGen faces another fail as anxiety drug flops a PhIII study — shares crater
VistaGen Therapeutics’ social anxiety drug flopped in a Phase III trial, the company announced Friday, adding to its list of programs that haven’t panned out.
The trial, which enrolled 209 patients according to clinicaltrials.gov, did not significantly change patient-reported anxiety levels compared to placebo. In the trial, patients diagnosed with social anxiety disorder took either VistaGen’s drug, PH94B, or a placebo, and then were challenged with a five-minute public speaking trial, during which they were asked to rate their anxiety.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.